Table 2.
OSA primary therapy device use over time (group A).
| Observed Value | Change from Baseline | |||||
|---|---|---|---|---|---|---|
| Na | Mean (SD) | Median (Q1, Q3) | na | Mean (SD) | Median (Q1, Q3) | |
| Percentage of nightsb | ||||||
| Baseline | 235 | 90.0 (19.1) | 100.0 (89.3, 100.0) | — | — | — |
| Day 1 to week 2 | 248 | 89.0 (23.9) | 100.0 (92.9, 100.0) | 228 | 1.4 (13.3) | 0.0 (0.0, 5.44) |
| Week 3 to 14 | 234 | 87.1 (26.1) | 98.9 (88.8, 100.0) | 214 | −0.5 (15.2) | 0.0 (−1.2, 4.6) |
| Week 15 to 27 | 212 | 88.2 (25.0) | 100.0 (90.8, 100.0) | 197 | 0.3 (13.0) | 0.0 (−1.1, 4.55) |
| Week 28 to 40c | 186 | |||||
| Week 28 to 40 | 68 | 89.2 (22.9) | 100.0 (90.7, 100.0) | 62 | 2.0 (12.3) | 0.0 (0.0, 4.55) |
| Week 30 to 40 | 118 | 89.5 (24.0) | 100.0 (94.7, 100.0) | 109 | 0.9 (12.4) | 0.0 (0.0, 5.14) |
| No. of hours per nightd | ||||||
| Baseline | 147 | 6.6 (1.4) | 6.6 (5.8, 7.4) | — | — | — |
| Day 1 to week 2 | 138 | 5.9 (2.1) | 6.4 (4.8, 7.4) | 126 | −0.7 (1.5) | −0.4 (−1.2, 0.2) |
| Week 3 to 14 | 134 | 5.7 (2.1) | 6.1 (4.9, 7.1) | 120 | −1.0 (1.7) | −0.6 (−1.5, 0.0) |
| Week 15 to 27 | 116 | 5.9 (2.1) | 6.2 (5.1, 7.2) | 106 | −0.9 (1.6) | −0.5 (−1.5, 0.0) |
| Week 28 to 40c | 102 | |||||
| Week 28 to 40 | 40 | 5.9 (2.1) | 6.1 (5.2, 7.4) | 34 | −0.9 (1.4) | −0.8 (−1.5, 0.0) |
| Week 30 to 40 | 62 | 6.0 (2.0) | 6.4 (5.4, 7.0) | 58 | −0.8 (1.7) | −0.5 (−1.1, 0.2) |
| Percentage of nights OSA device was used more than half of nighte | ||||||
| Baseline | 89 | 90.4 (26.1) | 100.0 (100.0, 100.0) | — | — | — |
| Day 1 to week 2 | 111 | 91.5 (23.2) | 100.0 (100.0, 100.0) | 83 | 4.1 (16.8) | 0.0 (0.0, 0.0) |
| Week 3 to 14 | 100 | 94.5 (18.8) | 100.0 (100.0, 100.0) | 76 | 5.3 (19.3) | 0.0 (0.0, 0.0) |
| Week 15 to 27 | 95 | 92.7 (21.8) | 100.0 (100.0, 100.0) | 73 | 3.6 (19.9) | 0.0 (0.0, 0.0) |
| Week 28 to 40c | 83 | |||||
| Week 28 to 40 | 27 | 94.4 (19.7) | 100.0 (100.0, 100.0) | 22 | 6.2 (21.8) | 0.0 (0.0, 0.0) |
| Week 30 to 40 | 56 | 94.7 (18.9) | 100.0 (100.0, 100.0) | 42 | 6.5 (20.5) | 0.0 (0.0, 0.0) |
OSA = obstructive sleep apnea, Q1 = 25th percentile, Q3 =75th percentile, SD = standard deviation. aNo. of participants with nonmissing value at visit. bAmong all participants (with either electronically retrievable or diary data). cData for this period were summarized separately for participants who did not enter the randomized withdrawal phase (week 28 to 40) and for participants who entered the 2-week randomized withdrawal phase (week 30–40). dAmong participants with electronically retrievable data. eAmong participants with diary data.